Province, China

Ran Sun



Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2011

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Ran Sun

Introduction

Ran Sun is a notable inventor based in Province, China. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic oligonucleotides. His work has the potential to impact the treatment of various immune-mediated disorders.

Latest Patents

Ran Sun holds a patent for an oligonucleotide with the nucleotide sequence of 5'-cctcctcctcctcctcctcctcct-3′ (SEQ ID NO: 1). This innovative oligonucleotide inhibits the proliferation of human PBMC activated by TLR9 agonist and interferon production from human PBMC induced by TLR9 agonist, HSV-1, flu virus, and serum from SLE patients. Furthermore, it has been shown to rescue mice from cytokine-mediated lethal shock. This oligonucleotide can be utilized as a remedy for the treatment of systemic lupus erythematosus (SLE), sepsis, multiple organ dysfunction syndromes, and other immune-mediated disorders.

Career Highlights

Ran Sun is currently associated with Changchun Huapu Biotechnology Co. Ltd., where he continues to advance his research and development efforts. His work is characterized by a commitment to innovation and the application of scientific knowledge to real-world health challenges.

Collaborations

Ran Sun collaborates with esteemed colleagues, including Liying Wang and Dali Hu, who contribute to his research endeavors and help drive forward the mission of their organization.

Conclusion

Ran Sun's contributions to biotechnology through his innovative patent and collaborative efforts highlight the importance of research in addressing complex health issues. His work exemplifies the potential of scientific innovation to improve patient outcomes and advance medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…